Alnylam Pharmaceuticals (ALNY) Current Deferred Tax Assets (2009 - 2010)

Alnylam Pharmaceuticals (ALNY) posted Current Deferred Tax Assets of $1.9 million for Q3 2010, little changed on a QoQ basis from $1.9 million in Q2 2010.

Alnylam Pharmaceuticals (ALNY) Current Deferred Tax Assets (2009 - 2010) Analysis & Trends

Alnylam Pharmaceuticals' Current Deferred Tax Assets history runs 2 years deep, the most recent figure standing at $1.9 million for Q3 2010.

  • Quarterly Current Deferred Tax Assets changed N/A year-over-year to $1.9 million in Q3 2010, while the trailing twelve-month figure through Sep 2010 was $1.9 million (changed N/A YoY) and the FY2009 annual result came in at $1.9 million, changed N/A from the prior year.
  • Current Deferred Tax Assets was $1.9 million for Q3 2010 at Alnylam Pharmaceuticals, roughly flat from $1.9 million in the prior quarter.
  • Across five years, Current Deferred Tax Assets topped out at $1.9 million in Q3 2010 and bottomed at $1.9 million in Q4 2009.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn -
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn -
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn
4 NuCana 279.75 Bn 279.75 Bn -
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn
7 Belite Bio 62.51 Bn 62.51 Bn -
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn
9 Revolution Medicines 37.78 Bn 37.78 Bn -
10 Alnylam Pharmaceuticals 35.71 Bn 32.70 Bn 959.66 Mn

Historic Data

Download Data
DateValue
Sep 30, 2010 1.94 Mn
Sep 30, 2010 1.94 Mn
Jun 30, 2010 1.94 Mn
Jun 30, 2010 1.94 Mn
Dec 31, 2009 1.94 Mn
Dec 31, 2009 1.94 Mn